Singapore's Aslan Pharmaceuticals Gets Second Oncology Candidate In Deal With Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Focused on in-licensing early-stage compounds to take advantage of efficiencies of running trials in Asia, Aslan previously obtained a HER2/EGFR inhibitor from Array BioPharma.
You may also be interested in...
ASLAN Completes Series A Funding For $12 Mn; Eyes More Financing Options With Spiraling Portfolio
MUMBAI - Singapore-based discovery research start-up ASLAN Pharmaceuticals reached a major milestone as it completed its Series A financing of $12 million. The fund will be utilized to develop the first set of in-licensed compounds by ASLAN
Bristol Basks In Broad Ipilimumab Label, Sets High Price
Labeling does not specify line of therapy, so the melanoma drug could see use beyond very late-stage refractory patient population studied in pivotal trial.
ASLAN CEO Carl Firth On A New Paradigm for Drug Development In Asia: An Interview With PharmAsia News
Asia continues to increase in importance for global clinical trial programs. Big pharmas such as Novartis and AstraZeneca are building up their own R&D sites while Eli Lilly and Pfizer are creating virtual R&D networks, taking advantage of the large naïve patient population and other efficiencies in Asia to accelerate drug development.